Showing 1 - 20 results of 119 for search '"противовоспалительное действие"', query time: 0.78s Refine Results
  1. 1
  2. 2
  3. 3
    Academic Journal

    Subject Terms: Annotatsiya. Ushbu ilmiy maqolada Zanjabil (Zingiber officinale) o'simligining shifobaxsh xususiyatlari va ularni asoslovchi biologik faol komponentlar haqida ilmiy manbalarga tayangan holda tahliliy ma'lumotlar taqdim etiladi. Tadqiqotlar zanjabilning antioksidant, yallig'lanishga qarshi, antimikrob, antidiabetik va gastroprotektiv ta'sirlarini ilmiy asosda tasdiqlaydi. Zanjabil ildizining tarkibida gingerol, shogaol, paradol, zingiberen, vitaminlar va minerallar mavjud bo'lib, ular inson salomatligini mustahkamlashda keng imkoniyatlarga ega. Kalit so'zlar. Zanjabil, Zingiber officinale, gingerol, shifobaxsh xususiyatlar, antioksidant, yallig'lanishga qarshi, antidiabetik, antimikrob, hazmni yaxshilash, tabiiy dori vositasi, fitoterapiya. Аннотация. В данной научной статье представлены аналитические сведения о целебных свойствах растения имбирь (Zingiber officinale) и его биологически активных компонентах. Научные исследования подтверждают антиоксидантные, противовоспалительные, антимикробные, антидиабетические и гастропротективные свойства имбиря. В корневище имбиря содержатся гингерол, шогаол, парадол, зингиберен, витамины и минералы, способствующие укреплению здоровья человека. Ключевые слова. Имбирь, Zingiber officinale, гингерол, лечебные свойства, антиоксиданты, противовоспалительное действие, антидиабетическое действие, антимикробный эффект, улучшение пищеварения, фитотерапия. Abstract. This scientific article presents an analytical overview of the medicinal properties of the ginger plant (Zingiber officinale) and its bioactive compounds. Research confirms the antioxidant, anti-inflammatory, antimicrobial, antidiabetic, and gastroprotective effects of ginger. The rhizome contains gingerol, shogaol, paradol, zingiberene, vitamins, and minerals that contribute to human health enhancement. Key words. Ginger, Zingiber officinale, gingerol, medicinal properties, antioxidant, anti-inflammatory, antidiabetic, antimicrobial, digestion, phytotherapy

  4. 4
    Academic Journal

    Subject Terms: Аннотация: В данной статье подробно анализируются лекарственные свойства каштана. Рассматриваются биологически активные вещества, содержащиеся в этом растении, и их антиоксидантное, противовоспалительное действие, а также влияние на улучшение кровообращения и укрепление иммунной системы. Кроме того, оценивается роль каштана в современной медицине на основе его использования в традиционной медицине, результатов клинических исследований и рекомендованных дозировок. Основная цель исследования — научное обоснование лечебного потенциала каштана и создание основы для дальнейших исследований. Ключие слово: каштан, декоративное растение, экология, лечебные свойства, биологически активные вещества, антиоксидантное действие, противовоспалительное, кровообращение, традиционная медицина, современная медицина, флавоноиды, экологические условия, фармакологическое значение, растительные экстракты, натуральные лекарственные средства. Abstract: This article provides an in-depth analysis of the medicinal properties of chestnut. It examines the biologically active compounds found in this plant and their antioxidant, anti-inflammatory effects, as well as their role in improving blood circulation and strengthening the immune system. Additionally, the article evaluates the role of chestnut in modern medicine based on its use in traditional medicine, clinical research findings, and recommended dosages. The main objective of the study is to scientifically substantiate the medicinal potential of chestnut and lay the foundation for further research. Keywords: chestnut, ornamental plant, ecology, medicinal properties, biologically active compounds, antioxidant effect, anti-inflammatory, blood circulation, traditional medicine, modern medicine, flavonoids, ecological conditions, pharmacological significance, plant extracts, natural medicinal remedies

  5. 5
    Academic Journal

    Subject Terms: Аннотация: В данной статье подробно анализируются лекарственные свойства каштана. Рассматриваются биологически активные вещества, содержащиеся в этом растении, и их антиоксидантное, противовоспалительное действие, а также влияние на улучшение кровообращения и укрепление иммунной системы. Кроме того, оценивается роль каштана в современной медицине на основе его использования в традиционной медицине, результатов клинических исследований и рекомендованных дозировок. Основная цель исследования — научное обоснование лечебного потенциала каштана и создание основы для дальнейших исследований. Ключие слово: каштан, декоративное растение, экология, лечебные свойства, биологически активные вещества, антиоксидантное действие, противовоспалительное, кровообращение, традиционная медицина, современная медицина, флавоноиды, экологические условия, фармакологическое значение, растительные экстракты, натуральные лекарственные средства. Abstract: This article provides an in-depth analysis of the medicinal properties of chestnut. It examines the biologically active compounds found in this plant and their antioxidant, anti-inflammatory effects, as well as their role in improving blood circulation and strengthening the immune system. Additionally, the article evaluates the role of chestnut in modern medicine based on its use in traditional medicine, clinical research findings, and recommended dosages. The main objective of the study is to scientifically substantiate the medicinal potential of chestnut and lay the foundation for further research. Keywords: chestnut, ornamental plant, ecology, medicinal properties, biologically active compounds, antioxidant effect, anti-inflammatory, blood circulation, traditional medicine, modern medicine, flavonoids, ecological conditions, pharmacological significance, plant extracts, natural medicinal remedies

  6. 6
  7. 7
    Academic Journal

    Source: Eurasian Journal of Medical and Natural Sciences; Vol. 5 No. 11 (2025): Eurasian Journal of Medical and Natural Sciences; 37-42 ; Евразийский журнал медицинских и естественных наук; Том 5 № 11 (2025): Евразийский журнал медицинских и естественных наук; 37-42 ; Yevrosiyo tibbiyot va tabiiy fanlar jurnali; Jild 5 Nomeri 11 (2025): Евразийский журнал медицинских и естественных наук; 37-42 ; 2181-287X

    File Description: application/pdf

  8. 8
    Academic Journal

    Source: Eurasian Journal of Medical and Natural Sciences; Vol. 5 No. 10 Part 2 (2025): Eurasian Journal of Medical and Natural Sciences; 134-142 ; Евразийский журнал медицинских и естественных наук; Том 5 № 10 Part 2 (2025): Евразийский журнал медицинских и естественных наук; 134-142 ; Yevrosiyo tibbiyot va tabiiy fanlar jurnali; Jild 5 Nomeri 10 Part 2 (2025): Евразийский журнал медицинских и естественных наук; 134-142 ; 2181-287X

    File Description: application/pdf

  9. 9
  10. 10
    Academic Journal

    Source: Meditsinskiy sovet = Medical Council; № 4 (2025); 53-58 ; Медицинский Совет; № 4 (2025); 53-58 ; 2658-5790 ; 2079-701X

    File Description: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/9024/7841; Lewin MR, Hick RW, Selim MA. Lichenoid Dermatitis of the Vulva: Diagnosis and Differential Diagnosis for the Gynecologic Pathologist. Adv Anat Pathol. 2017;24(5):278–293. https://doi.org/10.1097/PAP.0000000000000160.; Day T, Mauskar M, Selk A (eds.). Lichen sclerosus: ISSVD practical guide to diagnosis and management. Ad Médic, Lda.; 2024. 212 p. https://doi.org/10.59153/adm.ls.001.; Hong JJ, Mosca ML, Hadeler EK, Brownstone ND, Bhutani T, Liao WJ. Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. Dermatol Ther. 2021;11(3):833–844. https://doi.org/10.1007/s13555-021-00536-6.; Corazza M, Toni G, Virgili A, Borghi A. Plasma cell vulvitis: further confirmation of the diagnostic utility of dermoscopy. Int J Dermatol. 2018;57(12):e164-e165. https://doi.org/10.1111/ijd.14233.; Yeung J, Pauls RN. Anatomy of the Vulva and the Female Sexual Response. Obstet Gynecol Clin North Am. 2016;43(1):27–44. https://doi.org/10.1016/j.ogc.2015.10.011.; Смирнова ИО (ред.). Неинфекционные дерматозы вульвы: диагностика, лечение: иллюстрированное руководство для врачей. М.: ГЭОТАР-Медиа; 2021. 240 с. https://doi.org/10.33029/9704-6008-5-NDV-1-240.; Nunns D, Mandal D. The chronically symptomatic vulva: prevalence in primary health care. Genitourin Med. 1996;72(5):343–344. https://doi.org/10.1136/sti.72.5.343.; Raef HS, Elmariah SB. Vulvar Pruritus: A Review of Clinical Associations, Pathophysiology and Therapeutic Management. Front Med. 2021;8:649402. https://doi.org/10.3389/fmed.2021.649402.; Neill SM, Lewis FM, Tatnall FM, Cox NH; British Association of Dermatologists. British Association of Dermatologists’ guidelines for the management of lichen sclerosus 2010. Br J Dermatol. 2010;163(4):672–682. https://doi.org/10.1111/j.1365-2133.2010.09997.x.; Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. https://doi.org/10.1111/jdv.14891.; Lifits-Podorozhansky YM, Podorozhansky Y, Hoffstetter S, Gavard JA. Role of vulvar care guidelines in the initial management of vulvar complaints. J Low Genit Tract Dis. 2012;16(2):88–91. https://doi.org/10.1097/LGT.0b013e318232fd9a.; Lagro-Janssen AL, Sluis S. Effectiveness of treating non-specific pruritus vulvae with topical steroids: a randomized controlled trial. Eur J Gen Pract. 2009;15(1):29–33. https://doi.org/10.1080/13814780802705976.; Biro K, Thaçi D, Ochsendorf FR, Kaufmann R, Boehncke WH. Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebocontrolled study. Contact Dermatitis. 2003;49(2):80–84. https://doi.org/10.1111/j.0105-1873.2003.00184.x.; Proksch E, de Bony R, Trapp S, Boudon S. Topical use of dexpanthenol: a 70th anniversary article. J Dermatolog Treat. 2017;28(8):766–773. https://doi.org/10.1080/09546634.2017.1325310.; Мурашкин НН, Материкин АИ, Епишев РВ, Амбарчян ЭТ. Особенности течения и профилактики пеленочного дерматита у новорожденных и детей грудного возраста. Вопросы современной педиатрии. 2015;14(6):710–713. https://doi.org/10.15690/vsp.v14i6.1481.; Peltier E, de Salvo R, Ehret A, Trapp S, Lakomsky D, El Shazly MA. Evaluation of a 5% dexpanthenol-containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver-A real-world data observational study. Health Sci Rep. 2023;6(1):e1033. https://doi.org/10.1002/hsr2.1033.; Abiko Y, Tomikawa M, Shimizu M. Enzymatic conversion of pantothenylalcohol to pantothenic acid. J Vitaminol. 1969;15(1):59–69. https://doi.org/10.5925/jnsv1954.15.59.; Hrubša M, Siatka T, Nejmanová I, Vopršalová M, Kujovská Krčmová L, Matoušová K et al. Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1 , B2 , B3 , and B5 . Nutrients. 2022;14(3):484. https://doi.org/10.3390/nu14030484.; Williams RJ, Saunders DH. The effects of inositol, crystalline vitamin B(1) and “pantothenic acid” on the growth of different strains of yeast. Biochem J. 1934;28(5):1887–1893. https://doi.org/10.1042/bj0281887.; Ebner F, Heller A, Rippke F, Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol. 2002;3(6):427–433. https://doi.org/10.2165/00128071-200203060-0000; Proksch E, Berardesca E, Misery L, Engblom J, Bouwstra J. Dry skin management: practical approach in light of latest research on skin structure and function. J Dermatolog Treat. 2020;31(7):716–722. https://doi.org/10.1080/09546634.2019.1607024.; Stettler H, Kurka P, Lunau N, Manger C, Böhling A, Bielfeldt S et al. A new topical panthenol-containing emollient: Results from two randomized controlled studies assessing its skin moisturization and barrier restoration potential, and the effect on skin microflora. J Dermatolog Treat. 2017;28(2):173–180. https://doi.org/10.1080/09546634.2016.1214235.; Björklund S, Pham QD, Jensen LB, Knudsen NØ, Nielsen LD, Ekelund K et al. The effects of polar excipients transcutol and dexpanthenol on molecular mobility, permeability, and electrical impedance of the skin barrier. J Colloid Interface Sci. 2016;479:207–220. https://doi.org/10.1016/j.jcis.2016.06.054.; Stettler H, Kurka P, Wagner C, Sznurkowska K, Czernicka O, Böhling A, et al. A new topical panthenol-containing emollient: skin-moisturizing effect following single and prolonged usage in healthy adults, and tolerability in healthy infants. J Dermatolog Treat. 2017;28(3):251–257. https://doi.org/10.1080/09546634.2016.1218417.; Udompataikul M, Limpa-o-vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012;11(3):366–374. Available at: https://pubmed.ncbi.nlm.nih.gov/22395588.; Огородова ЛМ, Нагаева ТА, Ходкевич ЛВ. Эффективность декспантенола в комплексном лечении атопического дерматита у детей. Педиатрическая фармакология. 2003;1(3):54–56. Режим доступа: https://cyberleninka.ru/article/n/effektivnost-dekspantenola-v-kompleksnom-lecheniiatopicheskogo-dermatita-u-detey/viewer.; Кубанов АА, Аполихина ИА, Плахова КИ, Чернова НИ, Соколова АВ. Лишай склеротический и атрофический: клинические рекомендации. 2020.; Духанин АС. Водородный показатель (рН) основы топического лекарственного препарата: выбор оптимального значения и роль буферной системы. Клиническая дерматология и венерология. 2016;15(2):47-52. https://doi.org/10.17116/klinderma201615247-52.; Устинов МВ. Эмпирическая терапия воспалительных поражений кожи крупных складок. РМЖ. 2016;(14):945–948. Режим доступа: https://www.rmj.ru/articles/dermatologiya/Empiricheskaya_terapiya_vospalitelynyh_poragheniy_koghi_krupnyh_skladok.; Macura AB. In vitro susceptibility of dermatophytes to antifungal drugs: a comparison of two methods. Int J Dermatol. 1993;32(7):533–536. https://doi.org/10.1111/j.1365-4362.1993.tb02844.x.; Arévalo MP, Carrillo-Muñoz AJ, Salgado J, Cardenes D, Brió S, Quindós G, Espinel-Ingroff A. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother. 2003;51(1):163–166. https://doi.org/10.1093/jac/dkg018.

  11. 11
  12. 12
  13. 13
  14. 14
    Academic Journal

    Source: Медицинский совет, Vol 0, Iss 4, Pp 107-113 (2020)

  15. 15
  16. 16
    Academic Journal

    Source: Meditsinskiy sovet = Medical Council; № 2 (2023); 105-112 ; Медицинский Совет; № 2 (2023); 105-112 ; 2658-5790 ; 2079-701X

    File Description: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/7395/6596; Глухова Е.А., Мухортых В.А., Тамразова О.Б., Таганов А.В., Ревякина В.А. Предикторы тяжелого течения атопического дерматита. Вопросы питания. 2022;91(1):76–85. https://doi.org/10.33029/0042-8833-2022-91-1-76-85.; Siegfried E.C., Jaworski J.C., Kaiser J.D., Hebert A.A. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;(16):75. https://doi.org/10.1186/s12887-016-0607-9.; Mancini A.J., Kaulback K., Chamlin S.L. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol. 2008;25(1):1–6. https://doi.org/10.1111/j.1525-1470.2007.00572.x.; Kim J.P., Chao L.X., Simpson E.L., Silverberg J.I. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. J Am Acad Dermatol. 2016;75(4):681–687. https://doi.org/10.1016/j.jaad.2016.05.028.; Boguniewicz M., Fonacier L., Guttman-Yassky E., Ong P.Y., Silverberg J., Farrar J.R. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2. https://doi.org/10.1016/j.anai.2017.10.039.; Sayaseng K.Y., Vernon P. Pathophysiology and management of mild to moderate pediatric atopic dermatitis. J Pediatr Health Care. 2018;32(2):S2–S12. https://doi.org/10.1016/j.pedhc.2017.10.002.; Pustišek N., Živković M.V., Šitum M. Quality of life in fami lies with children with atopic dermatitis. Pediatr Dermatol. 2016;33(1):28–32. https://doi.org/10.1111/pde.12698.; Kuo I.H., Yoshida T., De Benedetto A., Beck L.A. The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):266–278. https://doi.org/10.1016/j.jaci.2012.12.1563.; Boguniewicz M., Leung D.Y.M. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233–246. https://doi.org/10.1111/j.1600-065X.2011.01027.x.; Irvine A.D., Mclean W.H.I., Leung D.Y.M. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315–1327. https://doi.org/10.1056/NEJMra1011040.; Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A. et al. Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. https://doi.org/10.1111/jdv.14891.; Eichenfield L.F., Tom W.L., Berger T.G., Krol A., Paller A.S., Schwarzenberg K. et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. https://doi.org/10.1016/j.jaad.2014.03.023.; Kapur S., Watson W., Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(2):52. https://doi.org/10.1186/s13223-018-0281-6.; Rathi S.K., D’Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol. 2012;57(4):251–259. https://doi.org/10.4103/0019-5154.97655.; Hughes J., Rustin M. Corticosteroids. Clin Dermatol. 1997;15(5):715–721. https://doi.org/10.1016/s0738-081x(97)00020-5.; Charman C.R., Morris A.D., Williams H.C. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931–936. https://doi.org/10.1046/j.1365-2133.2000.03473.x; Nghiem P., Pearson G., Langley R.G. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46(2):228–241. https://doi.org/10.1067/mjd.2002.120942.; Reitamo S. Tacrolimus: a topical immunomodulatory therapy for atopic dermatitis. J Allergy Clin Immunol. 2001;107(3):445–448. https://doi.org/10.1067/mai.2001.113521.; Santini M.P., Talora C., Seki T., Bolgan L., Dotto G.P. Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci USA. 2001;98(17):9575–9580. https://doi.org/10.1073/pnas.161299698.; Remitz A., Kyllönen H., Granlund H., Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol. 2001;107(1):196–197. https://doi.org/10.1067/mai.2001.112131.; Boguniewicz M., Fiedler V.C., Raimer S., Lawrence I.D., Hanifin J.M. A randomized, vehicle controlled trial of tacrolimus ointment for the treatment of atopic dermatitis in children. J Allergy Clin Immunol. 1998;102(4):637–644. https://doi.org/10.1016/s0091-6749(98)70281-7.; Hanifin J.M., Ling M.R., Langley R., Breneman D., Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol. 2001;44(1):S28–38. https://doi.org/10.1067/mjd.2001.109810.; Paller A., Eichenfield L.F., Leung D.Y.M., Steward D., Appell M. A 12-week study of tacrolimus oint ment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44(1):S47–57. https://doi.org/10.1067/mjd.2001.109813.; Soter N.A., Fleischer A.B., Webster G.F., Monroe E., Lawrence I. Tacrolimus ointment for the treat ment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44(1):S39–46. https://doi.org/10.1067/mjd.2001.109817.; Frankel H.C., Qureshi A.A. Comparative Effectiveness of Topical Calcineurin Inhibitors in Adult Patients with Atopic Dermatitis. Am J Clin Dermatol. 2012;13(2):113–123. https://doi.org/10.2165/11597780-000000000-00000.; Reitamo S., Rissanen J., Remitz A., Granlund H., Erkko P., Elg P. et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111(3):396–398. https://doi.org/10.1046/j.1523-1747.1998.00323.x.; Undre N.A., Moloney F.J., Ahmadi S., Stevenson P., Murphy G.M. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis British J Dermatol. 2009;160(3):665–669. https://doi.org/10.1111/j.1365-2133.2008.08974.x.; Eichenfield L.F., Tom W.L., Berger T.G., Krol A., Paller A.S., Schwarzenberger K. et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. https://doi.org/10.1016/j.jaad.2014.03.023.; Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. https://doi.org/10.1111/jdv.14891.; Sidbury R., Davis D.M., Cohen D.E., Cordoro K.M., Berger T.G., Bergman J.N. et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. https://doi.org/10.1016/j.jaad.2014.03.030.; Nakahara T., Koga T., Fukagawa S., Uchi H., Furue M. Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/emollient sequential therapy in patients with atopic dermatitis. J Dermatol. 2004;31(7):524–528. https://doi.org/10.1111/j.1346-8138.2004.tb00548.x.; Кубанова А.А., Кубанов А.А., Самцов А.В., Аравийская Е.Р. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. М.: Деловой экспресс; 2016. 748 с. Режим доступа: https://www.cnikvi.ru/docs/2335_maket_30.pdf.; Sugarman J.H., Fleischer A.B., Feldman S.R. Off-label prescribing in the treatment of dermatologic disease. J Am Acad Dermatol. 2002;47(2):217–223. https://doi.org/10.1067/mjd.2002.120469.; Gupta A.K., Versteeg S.G. Topical treatment of facial sebor rheic dermatitis: a systematic review. Am J Clin Dermatol. 2017;18(2):193–213. https://doi.org/10.1007/s40257-016-0232-2.; Kuhn A., Gensch K., Haust M., Schneider S.W., Bonsmann G., GaebeleinWissing N. et al. Efficacy of tacrolimus 0,1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2011;65(1):54–64. https://doi.org/10.1016/j.jaad.2010.03.037.; Saripalli Y.V., Gadzia J.E., Belsito D.V. Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact derma titis. J Am Acad Dermatol. 2003;49(3):477–482. https://doi.org/10.1067/s0190-9622(03)01826-7.; Pacor M.L., Di Lorenzo G., Martinelli N., Mansueto P., Friso S., Pellitteri M.E. et al. Tacrolimus oint ment in nickel sulphate-induced steroid-resistant allergic con tact dermatitis. Allergy Asthma Proc. 2006;27(6):527–531. https://doi.org/10.2500/aap.2006.27.2915.; Belsito D., Wilson D.C., Warshaw E., Fowler J., Ehrlich A., Anderson B. et al. A prospective ran domized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol. 2006;55(1):40–46. https://doi.org/10.1016/j.jaad.2006.03.025.; Katsarou A., Makris M., Papagiannaki K., Lagogianni E., Tagka A., Kalogeromitros D. Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study. Eur J Dermatol. 2012;22(2):192–196. https://doi.org/10.1684/ejd.2011.1615.; Alomar A., Puig L., Gallardo C.M., Valenzuela N. Topical tacro limus 0.1% ointment (Protopic®) reverses nickel contact der matitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. Contact Dermatitis. 2003;49(4):185–188. https://doi.org/10.1111/j.0105-1873.2003.0217.x.; Müller G.G., José N.K., de Castro R.S. Topical tacrolimus 0,03% as sole therapy in vernal keratoconjunctivitis: a randomized double-masked study. Eye Contact Lens. 2014;40(2):79–83. https://doi.org/10.1097/ICL.0000000000000001.; Матушевская Е.В., Коцарева О.Д., Матушевская Ю.И., Свирщевская Е.В. Поддерживающая терапия при атопическом дерматите у взрослых и детей. Клиническая дерматология и венерология. 2017;16(4):14–20. https://doi.org/10.17116/klinderma201716414-20.; Cavalié M., Ezzedine K., Fontas E., Montaudié H., Castela E., Bahadoran P. et al. Maintenance therapy of adult vitiligo with 0,1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135(4):970–974. https://doi.org/10.1038/jid.2014.527.; Luger T., Boguniewicz M., Carr W., Cork M., Deleuran M., Eichenfield L. et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26(4):306–315. https://doi.org/10.1111/pai.12331.

  17. 17
  18. 18
  19. 19
  20. 20